PURPOSE:Colon tumors with defective DNA mismatch repair (dMMR) have a well-characterized phenotype and accounts for approximately 15% to 20% of sporadic colon cancer as well as those colon cancer patients with Lynch syndrome. Although the presence of dMMR seems to be a favorable prognostic marker, data suggest that these patients do not respond as well to adjuvant chemotherapy. EXPERIMENTAL DESIGN: In this study, we examined the prognostic significance of tumor MMR deficiency and the presence of a specific mutation in BRAF (V600E) in a group of patients (n = 533) who participated in a randomized prospective clinical trial through the North Central Cancer Treatment Group. RESULTS: Tumors with dMMR were found to be associated with higher tumor grade (P = 0.001), proximal location (P < 0.0001), and improved overall and disease-free survival (P = 0.05 and 0.04, respectively). Among all cases examined, evaluation of the BRAF V600E mutation status revealed no statistically significant differences in either disease-free or overall survival. Patients were then grouped into four categories for further analysis: dMMR/BRAF(-), dMMR/BRAF(+), pMMR/BRAF(-), and pMMR/BRAF(+). The dMMR/BRAF(-) group had a significantly improved overall survival (5-year overall survival of 100% versus 73%, P = 0.002) compared with all others. The remaining three groups had very similar survival outcomes. An additional cohort of tumors previously classified as having dMMR were also tested for the BRAF V600E alteration. Results remained significant (P = 0.006) when the two groups were combined for analysis. CONCLUSIONS: Overall, these data suggest that the underlying molecular etiology of those tumors having dMMR may influence the disease outcome in these patients.
RCT Entities:
PURPOSE:Colon tumors with defective DNA mismatch repair (dMMR) have a well-characterized phenotype and accounts for approximately 15% to 20% of sporadic colon cancer as well as those colon cancerpatients with Lynch syndrome. Although the presence of dMMR seems to be a favorable prognostic marker, data suggest that these patients do not respond as well to adjuvant chemotherapy. EXPERIMENTAL DESIGN: In this study, we examined the prognostic significance of tumor MMR deficiency and the presence of a specific mutation in BRAF (V600E) in a group of patients (n = 533) who participated in a randomized prospective clinical trial through the North Central Cancer Treatment Group. RESULTS:Tumors with dMMR were found to be associated with higher tumor grade (P = 0.001), proximal location (P < 0.0001), and improved overall and disease-free survival (P = 0.05 and 0.04, respectively). Among all cases examined, evaluation of the BRAFV600E mutation status revealed no statistically significant differences in either disease-free or overall survival. Patients were then grouped into four categories for further analysis: dMMR/BRAF(-), dMMR/BRAF(+), pMMR/BRAF(-), and pMMR/BRAF(+). The dMMR/BRAF(-) group had a significantly improved overall survival (5-year overall survival of 100% versus 73%, P = 0.002) compared with all others. The remaining three groups had very similar survival outcomes. An additional cohort of tumors previously classified as having dMMR were also tested for the BRAFV600E alteration. Results remained significant (P = 0.006) when the two groups were combined for analysis. CONCLUSIONS: Overall, these data suggest that the underlying molecular etiology of those tumors having dMMR may influence the disease outcome in these patients.
Authors: Daniel J Weisenberger; Kimberly D Siegmund; Mihaela Campan; Joanne Young; Tiffany I Long; Mark A Faasse; Gyeong Hoon Kang; Martin Widschwendter; Deborah Weener; Daniel Buchanan; Hoey Koh; Lisa Simms; Melissa Barker; Barbara Leggett; Joan Levine; Myungjin Kim; Amy J French; Stephen N Thibodeau; Jeremy Jass; Robert Haile; Peter W Laird Journal: Nat Genet Date: 2006-06-25 Impact factor: 38.330
Authors: L A Aaltonen; R Salovaara; P Kristo; F Canzian; A Hemminki; P Peltomäki; R B Chadwick; H Kääriäinen; M Eskelinen; H Järvinen; J P Mecklin; A de la Chapelle Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245
Authors: K C Halling; A J French; S K McDonnell; L J Burgart; D J Schaid; B J Peterson; L Moon-Tasson; M R Mahoney; D J Sargent; M J O'Connell; T E Witzig; G H Farr; R M Goldberg; S N Thibodeau Journal: J Natl Cancer Inst Date: 1999-08-04 Impact factor: 13.506
Authors: J M Cunningham; C Y Kim; E R Christensen; D J Tester; Y Parc; L J Burgart; K C Halling; S K McDonnell; D J Schaid; C Walsh Vockley; V Kubly; H Nelson; V V Michels; S N Thibodeau Journal: Am J Hum Genet Date: 2001-08-24 Impact factor: 11.025
Authors: Sharlene Gill; Noralane M Lindor; Lawrence J Burgart; Regenia Smalley; Olga Leontovich; Amy J French; Richard M Goldberg; Daniel J Sargent; Jeremy R Jass; John L Hopper; Mark A Jenkins; Joanne Young; Melissa A Barker; Michael D Walsh; Andrew R Ruszkiewicz; Stephen N Thibodeau Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: Wade S Samowitz; Carol Sweeney; Jennifer Herrick; Hans Albertsen; Theodore R Levin; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701
Authors: J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau Journal: Cancer Res Date: 1998-08-01 Impact factor: 12.701
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: Bun Kim; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Won Ho Kim; Sung Pil Hong Journal: World J Gastroenterol Date: 2014-04-21 Impact factor: 5.742
Authors: Sandra Van Schaeybroeck; Wendy L Allen; Richard C Turkington; Patrick G Johnston Journal: Nat Rev Clin Oncol Date: 2011-02-15 Impact factor: 66.675